Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
Tokyo, JP
Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -12.94% | -17.09% | -16.85% | -5.43% | +4.96% | +3.14% | -4.21% | +25.42% | -5.43% | +16.54% | -26.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+27.2% ★ Q1'26: +31.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+252.2% ★ Q1'26: -85.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-9.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.6% Q1'26: +2.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.2% Q1'26: +1.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.57× ★ Q1'26: 0.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arata Igarashi | President, CEO & Chairman | — | male |
| Hiroaki Hayashi | Executive Officer | — | — |
| Hiroyoshi Kasai | GM of Pharmaceutical Development Division & Product Strategy Department and Director | — | male |
| Kazuhiko Fukuhara | Head of Public Relations Office | — | male |
| Kenichi Mori | Executive Officer | — | — |
| Kimihiko Sato | MD, Head of Healthcare Business Department & Director | — | male |
| Makoto Taniguchi | GM of Production Headquarters, Sagami Oi Factory Manager & Director | — | male |
| Mizuho Koike | Executive Officer | — | — |
| Noboru Yamazaki | Senior Executive Officer | — | — |
| Shigeo Kimura | Executive Officer | — | — |
| Tomoyuki Hirai | President, CEO & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4512.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
